- Home
- Products
- Customized ADCs
- CD38
- Anti-CD38 (Daratumumab)-SMCC-DM1 ADC
Anti-CD38 (Daratumumab)-SMCC-DM1 ADC (CAT#: ADC-W-824)
This ADC product is comprised of an anti-CD38 monoclonal antibody conjugated via a SMCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM1 binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- CD38
- Alternative Names
- CD38; CD38 molecule; CD38 antigen (p45); ADP-ribosyl cyclase 1; ADP ribosyl cyclase 1; NAD(+) nucleosidase; cADPr hydrolase 1; cyclic ADP-ribose hydrolase 1; ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase; T10;
- Target Entrez Gene ID
- 952
- Target UniProt ID
- P28907
- Overview
- The protein encoded by this gene is a non-lineage-restricted, type II transmembrane glycoprotein that synthesizes and hydrolyzes cyclic adenosine 5'-diphosphate-ribose, an intracellular calcium ion mobilizing messenger. The release of soluble protein and the ability of membrane-bound protein to become internalized indicate both extracellular and intracellular functions for the protein. This protein has an N-terminal cytoplasmic tail, a single membrane-spanning domain, and a C-terminal extracellular region with four N-glycosylation sites. Crystal structure analysis demonstrates that the functional molecule is a dimer, with the central portion containing the catalytic site. It is used as a prognostic marker for patients with chronic lymphocytic leukemia. Alternative splicing results in multiple transcript variants.
- Overview
- Human Anti-CD38 IgG1-kappa antibody, Daratumumab
- Generic name
- Daratumumab
- Host animal
- Human
- Species Reactivity
- Human
- Name
- SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate)
- Description
- Disulfide Linkers, are extensively exploited as a chemically labile linkage. Since the release of disulfide-linked drugs requires a cytoplasmic thiol cofactor, such as glutathione (GSH). Disulfides maintain stable at physiological pH and only when ADCs are internalized inside cells, the cytosol provides reducing environment including intracellular enzyme protein disulfide isomerase, or similar enzymes, drugs can be released.
- Name
- DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
- Description
- Derived from Maytansinoid,a group of cytotoxins structurally similar to rifamycin, geldanamycin, and ansatrienin. The eponymous natural cytotoxic agent maytansine is a 19-member lactam (ansa macrolide) structure originally isolated from the Ethiopian shrub Maytenus ovatus. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, which interfere the formation of microtubules and depolymerize already formed microtubules, inducing mitotic arrest in the intoxicated cells.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-E. coli Stx2A (Setoxaximab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2483)
- Anti-NGF (Tanezumab)-MC-MMAF ADC (CAT#: ADC-W-1672)
- Anti-GD2 (Dinutuximab)-SMCC-DM1 ADC (CAT#: ADC-W-2006)
- Anti-CTLA4 (Ipilimumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1001)
- Anti-MS4A1 (Tositumomab)-SMCC-DM1 ADC (CAT#: ADC-W-1580)
- Anti-APP (Bapineuzumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-707)
- Anti-ITGA4+ITGB7 (Crenezumab)-SMCC-DM1 ADC (CAT#: ADC-W-2498)
- Anti-CD3D (Teplizumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-833)
- Anti-TNFRSF8 (cAC10)-Mc-VC-PABC-MMAE ADC (CAT#: ADC-W-344)
- Anti-ERBB2 (Trastuzumab-LC-Q147)-DBCO-MMAF ADC (CAT#: ADC-W-256)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-824. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
CAT# | Product Name | Linker | Payload |
ADC-W-828 | Anti-CD38 (Daratumumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-829 | Anti-CD38 (Daratumumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-826 | Anti-CD38 (Daratumumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-827 | Anti-CD38 (Daratumumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-825 | Anti-CD38 (Daratumumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
CAT# | Product Name | Linker | Payload |
ADC-W-504 | Anti-EGFR (cetuximab)-SMCC-Doxorubicin ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | Doxorubicin |
ADC-W-2583 | Anti-EGFR (Zalutumumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-2598 | Anti-GPNMB (Glembatumumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-495 | Anti-EGFR (J2898A)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-2589 | Anti-EGFR (Cetuximab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
CAT# | Product Name | Linker | Payload |
ADC-W-2604 | Anti-ITGB3 (Tadocizumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-2532 | Anti-CD22 (Pinatuzumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-2571 | Anti-SLC34A2 (Lifastuzumab )-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-2527 | Anti-CD22-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-2610 | Anti-MS4A1 (Rituximab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.